journal article·2024-05-01Open access

Recent advances on two-dimensional material-based nanosystems for gene delivery

Mengjie Wang, Dan Li, Jiangtao Zhu, Junyu Liu, Yandong Yin, Yang Su, Chanyuan Jin, Juan Li, Can Yang Zhang

APL Materials· Volume 12· Issue 5

Abstract

Gene therapy has been extensively investigated and widely used in biomedical fields, such as cancer treatment. However, the most important issues for gene therapy are stability, targeting effect, transfection efficacy, and safety of gene formulation after administration, which seriously limit the further application of gene therapy in clinic. Therefore, gene delivery could be a promising strategy for overcoming these challenges. Two-dimensional (2D) materials are rising nanomaterials with excellent physical and chemical properties, including large specific surface area, easy modification, high conversion efficiency of light, and good biocompatibility, which have achieved promising applications as vehicles for gene delivery in the disease treatment. In this review, we first summarized the research progress of 2D material-based nanosystems for gene delivery to improve the therapeutic efficacy. We discussed that 2D material-based gene delivery nanosystems showed high therapeutic efficacy for many diseases treatment, especially cancer. Furthermore, we also proposed that surface modification of 2D materials might be a promising strategy to prepare multi-functional gene carriers for combination therapy with enhanced treatment efficacy. Finally, the future research progress, challenges, and prospects of 2D material-based nanosystems for gene therapy were discussed and concluded. Conclusively, we believe that 2D material-based nanosystems with good biocompatibility and high transfection efficiency would be potentially used in clinical settings to improve the therapeutic efficacy of gene therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · RNA Interference and Gene Delivery · MXene and MAX Phase Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Physics and Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology 1 , Beijing 100081, China

Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University 2 , Shenzhen 518055, China

Shenzhen Bay Laboratory 3 , Shenzhen 440300, China

Institute of Materials Research, Tsinghua Shenzhen International Graduate School, Tsinghua University 4 , Shenzhen 518055, China

Peking University School and Hospital of Stomatology 5 , Beijing 100081, China

Department of Materials Science, Shenzhen MSU-BIT University 6 , Shenzhen 518172, China

Key Laboratory of Industrial Biocatalysis, Ministry of Education, Tsinghua University 7 , Beijing 100084, China

References (100+)

Show source-provided references
1. The basic science of gene therapy10.1126/science.8493530 ↗
2. Second international conference on gene therapy of cancer10.1093/oxfordjournals.annonc.a058832 ↗
3. Gene therapy and metabolic engineering10.1006/mben.1999.0144 ↗
4. The era of gene therapy: From preclinical development to clinical application10.1016/j.drudis.2021.03.021 ↗
6. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: A first-in-human, phase I/II study10.1200/jco.18.02424 ↗
7. Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy10.1021/acsnano.6b06182 ↗
8. Esterase-activated charge-reversal polymer for fibroblast-exempt cancer gene therapy10.1002/adma.201603095 ↗
9. Ion channels in genetic epilepsy: From genes and mechanisms to disease-targeted therapies10.1124/pr.117.014456 ↗
10. Genetic treatment of a molecular disorder: Gene therapy approaches to sickle cell disease10.1182/blood-2015-09-618587 ↗
11. Advances in CRISPR/Cas-based gene therapy in human genetic diseases10.7150/thno.43360 ↗
12. Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach10.1016/j.addr.2020.03.005 ↗
13. Gene therapy clinical trials worldwide to 2017: An update10.1002/jgm.3015 ↗
14. Nucleic acid therapeutics using polyplexes: A journey of 50 years (and beyond)10.1021/cr5006793 ↗
15. Moving beyond ‘therapy’ and ‘enhancement’ in the ethics of gene editing10.1017/s0963180119000641 ↗
16. Ethics and social acceptability of a proposed clinical trial using maternal gene therapy to treat severe early-onset fetal growth restriction10.1002/uog.15880 ↗
17. Advances in lipid-lowering therapy through gene-silencing technologies10.1038/nrcardio.2018.3 ↗
18. Genome-editing technologies for gene and cell therapy10.1038/mt.2016.10 ↗
19. Insights on the intracellular trafficking of PDMAEMA gene therapy vectors10.1016/j.msec.2018.07.071 ↗
20. Recent advances in mRNA vaccine delivery10.1007/s12274-018-2091-z ↗
21. Versatile catalytic deoxyribozyme vehicles for multimodal imaging-guided efficient gene regulation and photothermal therapy10.1021/acsnano.8b08101 ↗
22. Metallohelix vectors for efficient gene delivery via cationic DNA nanoparticles10.1093/nar/gkab1277 ↗
23. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for efficient interleukin-12 cancer gene therapy10.1002/adma.202006189 ↗
24. Appraisal for the potential of viral and nonviral vectors in gene therapy: A review10.3390/genes13081370 ↗
25. Vectors for glioblastoma gene therapy: Viral and non-viral delivery strategies10.3390/nano9010105 ↗
26. Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine10.1016/j.gendis.2017.04.001 ↗
27. Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy10.3390/cancers13081863 ↗
28. Combined delivery of a TGF-β inhibitor and an adenoviral vector expressing interleukin-12 potentiates cancer immunotherapy10.1016/j.actbio.2017.05.009 ↗
29. IL-1α and complement cooperate in triggering local neutrophilic inflammation in response to adenovirus and eliminating virus-containing cells10.1371/journal.ppat.1004035 ↗
30. Immune response to helper dependent adenoviral mediated liver gene therapy: Challenges and prospects10.2174/156652307782151452 ↗
31. A core viral protein binds host nucleosomes to sequester immune danger signals10.1038/nature18317 ↗
32. In situ gene therapy via AAV-CRISPR-Cas9-mediated targeted gene regulation10.1016/j.ymthe.2018.04.017 ↗
33. Adeno-associated virus vector as a platform for gene therapy delivery10.1038/s41573-019-0012-9 ↗
34. Protease-activatable adeno-associated virus vector for gene delivery to damaged heart tissue10.1016/j.ymthe.2019.01.015 ↗
35. Emerging issues in AAV-mediated in vivo gene therapy10.1016/j.omtm.2017.11.007 ↗
36. Overcoming the host immune response to adeno-associated virus gene delivery vectors: The race between clearance, tolerance, neutralization, and escape10.1146/annurev-virology-101416-041936 ↗
37. Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes10.1016/j.jconrel.2022.04.013 ↗
38. Rational design of cationic lipids for siRNA delivery10.1038/nbt.1602 ↗
39. Lipid-based DNA therapeutics: Hallmarks of non-viral gene delivery10.1021/acsnano.8b07858 ↗
40. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy10.1016/j.apmt.2018.05.002 ↗
41. A mixed-surface polyamidoamine dendrimer for in vitro and in vivo delivery of large plasmids10.3390/pharmaceutics12070619 ↗
42. Nonviral gene delivery with cationic glycopolymers10.1021/acs.accounts.8b00665 ↗
43. Dex-Aco coating simultaneously increase the biocompatibility and transfection efficiency of cationic polymeric gene vectors10.1016/j.jconrel.2019.04.035 ↗
44. Sugar-based gene delivery systems: Current knowledge and new perspectives10.1016/j.carbpol.2017.11.105 ↗
45. Chitosan for gene delivery: Methods for improvement and applications10.1016/j.cis.2019.03.007 ↗
46. Enhanced blood–brain barrier penetration and glioma therapy mediated by a new peptide modified gene delivery system10.1016/j.biomaterials.2014.10.034 ↗
47. Native chemical ligation for conversion of sequence-defined oligomers into targeted pDNA and siRNA carriers10.1016/j.jconrel.2014.02.015 ↗
48. Photothermal combined gene therapy achieved by polyethyleneimine-grafted oxidized mesoporous carbon nanospheres10.1016/j.biomaterials.2016.05.033 ↗
49. Antitumoral cascade-targeting ligand for IL-6 receptor-mediated gene delivery to glioma10.1016/j.ymthe.2017.04.023 ↗
50. Octopus-like flexible vector for noninvasive intraocular delivery of short interfering nucleic acids10.1021/acs.nanolett.9b02596 ↗
51. Non-viral nanocarriers for CRISPR-Cas9 gene editing system delivery10.1016/j.cej.2022.135116 ↗
52. Peptide-based gene delivery vectors10.1039/c8tb03124j ↗
53. Strategies for cancer gene-delivery improvement by non-viral vectors10.1016/j.ijpharm.2021.120291 ↗
54. Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery10.1016/j.actbio.2020.07.027 ↗
55. Non viral vectors in gene therapy—An overview10.7860/jcdr/2015/10443.5394 ↗
56. Polymeric siRNA gene delivery–transfection efficiency versus cytotoxicity10.1016/j.jconrel.2019.10.046 ↗
57. Design of polymeric gene carriers for effective intracellular delivery10.1016/j.tibtech.2018.02.006 ↗
58. Bifunctional aptasensor based on novel two-dimensional nanocomposite of MoS2 quantum dots and g-C3N4 nanosheets decorated with chitosan-stabilized Au nanoparticles for selectively detecting prostate specific antigen10.1016/j.aca.2018.06.070 ↗
59. Electric field effect in atomically thin carbon films10.1126/science.1102896 ↗
60. Atomic-layer graphene as a saturable absorber for ultrafast pulsed lasers10.1002/adfm.200901007 ↗
61. Two-dimensional non-layered selenium nanoflakes: Facile fabrications and applications for self-powered photo-detector10.1088/1361-6528/aafc0f ↗
62. 2D nonlayered selenium nanosheets: Facile synthesis, photoluminescence, and ultrafast photonics10.1002/adom.201700884 ↗
63. Two-dimensional (2D) hybrid nanomaterials for diagnosis and treatment of cancer10.1016/j.jddst.2022.103268 ↗
64. Modification of mono-layer MoS2 through post-deposition treatment and oxidation for enhanced optoelectronic properties10.1063/5.0189378 ↗
65. 2D nanomaterials for cancer theranostic applications10.1002/adma.201902333 ↗
66. Biofunctionalization of graphene and its two-dimensional analogues and synthesis of biomimetic materials: A review10.1007/s10853-021-06787-0 ↗
67. 2D materials-based nanomedicine: From discovery to applications10.1016/j.addr.2022.114268 ↗
68. Two-dimensional biomaterials: Material science, biological effect and biomedical engineering applications10.1039/d0cs01138j ↗
69. Chirality-dependent tumor phototherapy using amino acid-engineered chiral phosphorene10.1021/acsami.2c19291 ↗
70. 2D WS2 nanosheets for ultrasound-triggered and mitochondria-targeted piezodynamic cancer therapy synergized with energy metabolism-targeted chemotherapy10.1002/adma.202300437 ↗
71. A multifunctional cascade bioreactor based on hollow-structured Cu2MoS4 for synergetic cancer chemo-dynamic therapy/starvation therapy/phototherapy/immunotherapy with remarkably enhanced efficacy10.1002/adma.201905271 ↗
72. Bottom-up synthesis of metal-ion-doped WS2 nanoflakes for cancer theranostics10.1021/acsnano.5b04606 ↗
73. In situ engineering of tumor-associated macrophages via a nanodrug-delivering-drug (β-elemene@stanene) strategy for enhanced cancer chemo-immunotherapy10.1002/anie.202308413 ↗
74. Graphene and other 2D materials: A multidisciplinary analysis to uncover the hidden potential as cancer theranostics10.7150/thno.40068 ↗
75. Recent advances in ultrathin two-dimensional nanomaterials10.1021/acs.chemrev.6b00558 ↗
76. High-yield production of graphene by liquid-phase exfoliation of graphite10.1038/nnano.2008.215 ↗
77. Ambient-stable two-dimensional titanium carbide (MXene) enabled by iodine etching10.1002/anie.202015627 ↗
78. Is chemical vapor deposition of monolayer WSe2 comparable to other synthetic routes?10.1063/5.0175469 ↗
79. Anisotropic photoresponse of the ultrathin GeSe nanoplates grown by rapid physical vapor deposition10.1021/acsami.8b19306 ↗
80. Advances in subcritical hydro-/solvothermal processing of graphene materials10.1002/adma.201605473 ↗
81. Graphene and related materials for the internet of bio-nano things10.1063/5.0153423 ↗
82. The rise of graphene10.1038/nmat1849 ↗
83. Improved synthesis of graphene oxide10.1021/nn1006368 ↗
84. The chemistry of graphene oxide10.1039/b917103g ↗
85. Progress in the functional modification of graphene/graphene oxide: A review10.1039/d0ra01068e ↗
86. XPS and structural studies of high quality graphene oxide and reduced graphene oxide prepared by different chemical oxidation methods10.1016/j.ceramint.2019.04.165 ↗
87. Graphene and graphene oxide: Synthesis, properties, and applications10.1002/adma.201001068 ↗
88. Graphene oxide incorporated PLGA nanofibrous scaffold for solid phase gene delivery into mesenchymal stem cells10.1166/jnn.2018.14362 ↗
89. Reaction between graphene oxide and intracellular glutathione affects cell viability and proliferation10.1021/acsami.0c17523 ↗
90. Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts10.1021/am200428v ↗
91. Orthogonal adsorption onto nano-graphene oxide using different intermolecular forces for multiplexed delivery10.1002/adma.201301183 ↗
92. Graphene-related nanomaterials: Tuning properties by functionalization10.1039/c3nr33218g ↗
93. Graphene oxide: An efficient material and recent approach for biotechnological and biomedical applications10.1016/j.msec.2018.01.004 ↗
94. Surface functionalization of chemically reduced graphene oxide for targeted photodynamic therapy10.1166/jbn.2015.2055 ↗
95. Noncovalent functionalization of graphene and graphene oxide for energy materials, biosensing, catalytic, and biomedical applications10.1021/acs.chemrev.5b00620 ↗
96. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini10.1073/pnas.98.3.1200 ↗
97. Graphene based gene transfection10.1039/c0nr00680g ↗
98. Generation of integration-free induced neurons using graphene oxide-polyethylenimine10.1002/smll.201601993 ↗
99. PAMAM dendrimers as promising nanocarriers for RNAi therapeutics10.1016/j.mattod.2015.06.003 ↗
100. A polyamidoamne dendrimer functionalized graphene oxide for DOX and MMP-9 shRNA plasmid co-delivery10.1016/j.msec.2016.09.035 ↗